A dose-response study in mice of a tetravalent recombinant dengue envelope domain III protein secreted from insect cells
Related Experiment Video
Updated: Dec 17, 2025
A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease
Published on: April 28, 2019
Lijun Shao1, Zheng Pang2, Yu Bi1
1Key Laboratory of health inspection and quarantine of Weifang, School of Public Health, WeiFang Medical University, Weifang 261053, China.
Background:
DENV is the most globally prevalent mosquito-transmitted virus. Induction of a broadly and potently immune response is desirable for dengue vaccine development.
Methods:
Several formulations of secreted tetravalent EDIII protein containing different amounts of antigen from eukaryotic cells were used to evaluate the immune responses in mice.
Results:
We demonstrated that the tetravalent protein induced humoral immunity against all four serotypes of DENV, even at the lowest dose assayed. Besides, cellular immunities against DENV-1 and DENV-2 were elicited by medium dose group. Importantly, the immune responses induced by the tetravalent protein were functional in clearing DENV-2 in circulation of mice.
Conclusions:
We believe that the tetravalent secreted EDIII protein is a potential vaccine candidate against DENV and suggest further detailed studies of this formulation in nonhuman primates.
